NASDAQ
3.99USD
+0.09 (+2.31%)
We have scored 4 news catalysts on Liminatus Pharma, Inc. Class A Common Stock (LIMN) over the past 12 months. The biggest single-day move next to one of them came Jul 2, 2026, when LIMN closed +24.0%: “Dow Gains Over 250 Points; US Jobs Rise By 57,000 In June”. Coverage across the window leans positive (average ticker sentiment +0.25). Most of the impact sits in interest rate sensitivity duration and sector consumer.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.4M
P/E
—
EPS
—
Beta
0.71
52W range
3.29-141.5
Day range
3.80–4.08
Open
3.80
Prev close
3.90
Volume
17.9K
Avg volume
494.4K
Dividend
0.00
IPO
2025-05-01
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Liminatus Pharma, Inc. Class A Common Stock — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LIMN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
